Methazolamide
規格
554-57-4CAS番号
N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamideIUPAC名
C5H8N4O3S2化学式
236.3 g/mol分子量
methazolamide; 554-57-4; Methenamide; Neptazane; Neptazaneat; Naptazane; Metazolamida; N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide; C5H8N4O3S2; DTXSID1023281; Methazolamide, (Z)-; MFCD00083416; L584601; NSC-758426; N-(3-Methyl-5-Sulfamoyl-1,3,4-Thiadiazol-2(3h)-Ylidene)acetamide; Acetamide, N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-; N-[(2E)-3-Methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide; MLS000028532; CHEBI:6822; DA43GW06P1; VVP808; W733B0S9SD; VVP-808; Acetamide, N-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene)-; N-(3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene)acetamide; NCGC00016508-01; Metazolamide; CAS-554-57-4; SMR000058287; (NE)-N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide; 2101958-72-7; L-584601; Metazolamide [DCIT]; Methazolamidum; Acetamide, N-(5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene)-, (N(Z))-; Metazolamida [INN-Spanish]; Methazolamidum [INN-Latin]; 1164547-86-7; HSDB 3269; SR-05000001844; EINECS 209-066-7; BRN 0232387; UNII-W733B0S9SD; 2-Acetylimino-3-methyl-.delta.(4)-1,3,4-thiadiazoline-5-sulfonamide; 3-methyl-2-(2-oxo-1-azapropylidene)-1,3,4-thiadiazoline-5-sulfonamide; 5-Acetylimino-4-methyl-.delta.(2)-1,3,4-thiadiazoline-2-sulfonamide; N-(4-Methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)acetamide; N-(5-(Aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene)acetamide #; N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide;; Acetamide, N-(4-methyl-2-sulfamoyl-.delta.2-1,3,4-thiadiazolin-5-ylidene)-; (Z)-methazolamide; Neptazane (TN); Methazolamide [USP:INN:BAN:JAN]; Methazolamide, MZA; Prestwick_1007; Methazolamide (MZA); Spectrum_001615; Opera_ID_717; Methazolamide (Standard); CHEMBL19; MZA3; Prestwick0_000802; Prestwick1_000802; Prestwick2_000802; Prestwick3_000802; Spectrum2_001543; Spectrum3_001914; Spectrum4_000190; Spectrum5_001006; 2-Acetylimino-3-methyl-delta(sup 4)-1,3,4-thiadiazoline-5-sulfonamide; 5-Acetylimino-4-methyl-delta(sup 2)-1,3,4-thiadiazoline-2-sulfonamide; METHAZOLAMIDE [MI]; METHAZOLAMIDE [INN]; METHAZOLAMIDE [JAN]; N-(4-Methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)acetamide; cid_4100; METHAZOLAMIDE [HSDB]; UNII-DA43GW06P1; Oprea1_161738; SCHEMBL24686; SCHEMBL24687; BSPBio_000663; BSPBio_003508; KBioGR_000739; KBioSS_002095; METHAZOLAMIDE [VANDF]; 4-27-00-08221 (Beilstein Handbook Reference); MLS001146905; DivK1c_000582; METHAZOLAMIDE [MART.]; SPECTRUM1503252; SPBio_001386; SPBio_002584; METHAZOLAMIDE [USP-RS]; METHAZOLAMIDE [WHO-DD]; BPBio1_000731; CHEMBL288100; DTXCID503281; GTPL6828; Methazolamide (JAN/USP/INN); orb1224682; orb1310931; US10172837, Methazolamide; SCHEMBL13825893; BDBM10881; CHEBI:94513; HMS501N04; HY-B0553R; KBio1_000582; KBio2_002095; KBio2_004663; KBio2_007231; KBio3_003013; FLOSMHQXBMRNHR-DAXSKMNVSA-N; FLOSMHQXBMRNHR-QPJJXVBHSA-N; Methazolamide, >=98% (HPLC); NINDS_000582; BDBM315269; GLXC-02995; HMS1570B05; HMS1922M19; HMS2093A05; HMS2097B05; HMS2234L03; HMS3259H05; HMS3372G12; HMS3652E21; HMS3714B05; HMS3747O09; HMS5082N19; Pharmakon1600-01503252; METHAZOLAMIDE [ORANGE BOOK]; HY-B0553; MSK10633; VWC14230; Tox21_110464; BDBM50013792; CCG-39321; EBC-06359; METHAZOLAMIDE [USP MONOGRAPH]; NSC758426; SBB037875; AKOS015897587; AKOS024464790; AKOS026749792; CCG-266836; DB00703; KS-5328; NC00618; NSC 758426; SB17307; Acetamide, N-(4-methyl-2-sulfamoyl-delta(sup 2)-1,3,4-thiadiazolin-5-ylidene)-; IDI1_000582; N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide; NCGC00016508-03; NCGC00016508-04; NCGC00016508-18; NCGC00018188-01; NCGC00018188-02; NCGC00018188-03; NCGC00018188-04; NCGC00018188-05; NCGC00018188-06; NCGC00018188-07; NCGC00022950-03; NCGC00022950-04; NCGC00178022-01; NCGC00178022-02; AC-32472; AS-13272; ST081366; SY111372; SBI-0051804.P002; DB-052736; AB00490015; M1579; NS00007349; S4039; SW197085-3; EN300-51717; C07764; D00655; D81966; AB00052336_04; EN300-7412532; Methazolamide, VETRANAL(TM), analytical standard; Q1149099; SR-05000001844-1; SR-05000001844-2; SR-05000001844-3; BRD-K13356952-001-15-2; BRD-K13356952-001-25-1; BRD-K13356952-001-26-9; BRD-K13356952-001-27-7; BRD-K71053238-001-03-6; BRD-K71053238-001-04-4; Q27276292; Z728800602; (NZ)-N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2-ylidene)acetamide; Methazolamide, United States Pharmacopeia (USP) Reference Standard; (E)-N-(3-methyl-5-sulfamoyl-1,3,4-thiadiazol-2(3H)-ylidene)acetamide; [N(E)]-N-[5-(Aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide; Acetamide, N-[5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]-, [N(E)]-; N-(4-METHYL-2-SULFAMOYL-.DELTA.(SUP 2)-1,3,4-THIADIAZOLIN-5-YLIDENE)ACETAMIDE; N-[(2Z)-3-methyl-5-sulfamoyl-2,3-dihydro-1,3,4-thiadiazol-2-ylidene]acetamide別名
